Posted by Michael Wonder on 20 Feb 2022
New PBS listing to help fight chronic graft versus host disease
20 February 2022 - From 1 March 2022, Australians with chronic graft versus host disease, a complication that can occur when patients undergoing cancer treatment receive transplanted stem cells from a donor, will have access to a new treatment through the Pharmaceutical Benefits Scheme.
Uvadex (methoxsalen) will be used as part of an integrated, closed system extracorporeal photopheresis service for the treatment of chronic graft versus host disease.
